Clinical Trial Update: Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of Repeat Doses of GSK2982772 in Subjects With Psoriasis [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating repeat dosing of GSK2982772 in psoriasis, focusing on safety, tolerability, PK/PD, and efficacy; results completed with posted r…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Psoriasis

Drugs mentioned

• GSK2982772 (GSK2982772)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Psoriasis | Phase 2 | Status: COMPLETED | Results posted: 2019-08-22